LS-SCLC
Oncology · 2025–2025
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| durvalumab Limited-stage small cell lung cancer (LS-SCLC) in patients whose disease has not progressed during or following platinum-based chemoradiation therapy. | Jul 2025 | Recommended with restriction | input received Rare Cancers Australia · Thoracic Oncology Group · Lung Foundation Australia |
Who spoke
Rare Cancers Australia · Thoracic Oncology Group · Lung Foundation Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.